Long-Term Vyepti Therapy Reduced Pain, Headache Frequency, & Disability in People with Chronic Migraine

Adults with chronic migraine who received intravenous (IV) treatment with Vyepti (eptinezumab-jjmr; Lundbeck, Deerfield, IL) at 300 mg every 12 weeks showed early reductions in migraine frequency, pain severity, and disability, which were sustained over 2 years. Results of a post-hoc analysis of the PREVAIL (NCT02985398) clinical trial were presented at the 66th Annual Scientific Meeting of the American Headache Society (AHS). These findings suggest that long-term treatment with Vyepti may reduce the impact of migraine, with reductions in monthly headache days (MHDs) being potentially indicative of preventive treatment optimization.

PREVAIL was a single-arm, open-label, phase 3 trial evaluating the long-term safety, tolerability, and effectiveness of Vyepti treatment for adults with chronic migraine. There were 2 48-week treatment phases with outcomes assessed by questionnaire. In the post-hoc analysis, changes in MHD frequency, monthly days with impact on work, school, home or social life, and migraine frequency-severity index (FSI) score (overlaying MHD frequency with pain severity) were assessed based on participant responses.

In terms of MHDs:

• MHDs decreased by 64% from baseline (15.8) to week 12 (5.7) and were sustained until week 104.
• The proportion of participants reporting <4 MHDs increased from 4% at baseline to 61% at week 12 and was sustained until week 104.
• The proportion of participants reporting 0 MHDs increased from 9% at week 12 to 23% at week 104.
• Of the 73 participants who reported >14 MHDs at baseline, <4 MHDs were reported by 56% at week 12 and 62% at week 104.

Additionally:

• Mean reported pain severity score was 7.3 at baseline, 5.5 at week 12, and 4.5 at week 104.
• FSI score decreased by 69% from baseline (11.4) to week 12 (3.5) and was sustained until week 104.
• Reported disability due to migraine reduced in parallel with MHD reductions.